Empagliflozin and cardiovascular outcomes in patients with chronic kidney disease: the EMPA-KIDNEY trial

Empagliflozin and cardiovascular outcomes in patients with chronic kidney disease: the EMPA-KIDNEY trial

Bibliografske podrobnosti
Main Authors:	Preiss, D, Herrington, W, Haynes, R
Format:	Conference item
Jezik:	English
Izdano:	American Heart Association 2022

Podobne knjige/članki

Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
od: Mayne, K, et al.
Izdano: (2024)

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
od: Staplin, N, et al.
Izdano: (2023)

Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial
od: Mayne, KM, et al.
Izdano: (2024)

Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA–KIDNEY
od: Nangaku, M, et al.
Izdano: (2024)

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
od: Staplin, N, et al.
Izdano: (2023)

Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA‐REG OUTCOME® trial
od: Takashi Kadowaki, et al.
Izdano: (2019-05-01)

Empagliflozin in patients with chronic kidney disease
od: Herrington, WG, et al.
Izdano: (2022)

Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial
od: Herrington, W, et al.
Izdano: (2022)

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
od: Herrington, W, et al.
Izdano: (2018)

Empagliflozin in patients with autosomal dominant polycystic kidney disease (EMPA-PKD): study protocol for a randomised controlled trial
od: Roland Schmitt, et al.
Izdano: (2024-12-01)

Effect of Qualifying Atherosclerotic Cardiovascular Disease Diagnosis Proximity on Cardiovascular Risk and Benefit of Empagliflozin in the EMPA-REG OUTCOME Trial
od: Ayodele Odutayo, MD, DPhil, et al.
Izdano: (2024-07-01)

Effects of empagliflozin on fluid overload, weight and blood pressure in chronic kidney disease
od: Mayne, K, et al.
Izdano: (2023)

Are the cardiovascular risk reductions seen with empagliflozin in the EMPA-REG OUTCOME trial explained by conventional cardiovascular risk factors?
od: Coleman, R, et al.
Izdano: (2017)

Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial
od: David Fitchett, et al.
Izdano: (2021-12-01)

Long-term effects of empagliflozin in patients with chronic kidney disease
od: Herrington, WG, et al.
Izdano: (2024)

Empagliflozin and Rapid Kidney Function Decline Incidence in Type 2 Diabetes: An Exploratory Analysis From the EMPA-REG OUTCOME Trial
od: Samy Hadjadj, et al.
Izdano: (2024-03-01)

Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial
od: Subodh Verma, et al.
Izdano: (2021-08-01)

1. Effect of empagliflozin on cardiovascular death in subgroups by age: Results from EMPA-REG outcome
od: Mahmoud Elrouby, et al.
Izdano: (2017-10-01)

Impact of primary kidney disease on the effects of empagliflozin in patients with CKD
od: Judge, PK, et al.
Izdano: (2023)

Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure
od: Hundertmark, MJ, et al.
Izdano: (2021)

Design and rationale of the EMPA‐VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure
od: Moritz J. Hundertmark, et al.
Izdano: (2021-08-01)

Can the cardiovascular risk reductions observed with empagliflozin in the EMPA‐REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?
od: Coleman, RL, et al.
Izdano: (2020)

Dapagliflozin versus empagliflozin in patients with chronic kidney disease
od: Hilmi Alnsasra, et al.
Izdano: (2023-08-01)

Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial
od: Antonio Ceriello, et al.
Izdano: (2020-10-01)

Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME
od: Pierpaolo Pellicori, et al.
Izdano: (2020-12-01)

Cost-effectiveness analysis of empagliflozin in the treatment of patients with type 2 diabetes and established cardiovascular disease in Italy, based on the results of the EMPA-REG OUTCOME study
od: Sergio Iannazzo, et al.
Izdano: (2017-10-01)

Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trial
od: David Fitchett, et al.
Izdano: (2024-07-01)

Cost effectiveness of empagliflozin in adult patients with chronic kidney disease in the Netherlands
od: Bart Slob, et al.
Izdano: (2024-01-01)

Cost effectiveness of empagliflozin in adult patients with chronic kidney disease in the Netherlands.
od: Bart Slob, et al.
Izdano: (2024-01-01)

Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial
od: João Pedro Ferreira, et al.
Izdano: (2021-04-01)

Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease
od: Zhu, D, et al.
Izdano: (2025)

Effect of empagliflozin on ventricular arrhythmias in patients with type 2 diabetes treated with an implantable cardioverter-defibrillator: the EMPA-ICD trial
od: Shinya Fujiki, et al.
Izdano: (2024-06-01)

Assessment of cardiac energy metabolism, function, and physiology in patients with heart failure taking empagliflozin: the randomized, controlled EMPA-VISION trial
od: Hundertmark, MJ, et al.
Izdano: (2023)

Kidney disease trials for the 21st century: innovations in design and conduct
od: Herrington, W, et al.
Izdano: (2019)

The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease: the EMPA-CARD randomized controlled trial
od: Sepehr Gohari, et al.
Izdano: (2022-11-01)

Empagliflozin Is Not Renoprotective in Non-Diabetic Rat Models of Chronic Kidney Disease
od: Silvie Hojná, et al.
Izdano: (2022-10-01)

The prevention and management of chronic kidney disease among patients with metabolic syndrome
od: Zhu, D, et al.
Izdano: (2025)

Journey from EMPA-REG to CARMELINA to EMPEROR-Preserved: Empagliflozin/linagliptin in heart failure and diabetes
od: Sharvil S Gadve, et al.
Izdano: (2022-01-01)

Chronic kidney disease, heart failure and neprilysin inhibition
od: Haynes, R, et al.
Izdano: (2019)

A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease
od: Schlackow, I, et al.
Izdano: (2017)